[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607411":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":24,"responsibleParty":31,"collaborators":24,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":24,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":24,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":57,"whyStopped":24,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":24},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control: Oxytocin only","EXPERIMENTAL","Description: Participants receive standard intraoperative uterotonic therapy with oxytocin according to hospital protocol immediately after delivery of the baby and placenta. Standard perioperative care (spinal anesthesia, prophylactic antibiotics, fluid management, monitoring) is provided. Rescue uterotonic measures and transfusion given as clinically indicated.",[13],"Drug: Oxytocin",{"label":15,"type":10,"description":16,"interventionNames":17},"Intervention: Oxytocin + Rectal Misoprostol","Participants receive the same oxytocin regimen as Arm 1 plus a single rectal dose of misoprostol (600-1000 µg depending on risk profile) administered immediately after delivery of the baby and placenta. Standard perioperative care is identical to Arm 1. Rescue uterotonic measures and transfusion given as clinically indicated.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Oxytocin","Intravenous oxytocin administered per hospital protocol immediately after delivery of the baby and placenta (example regimen: 10 IU slow IV bolus followed by infusion e.g., 20 IU in 500-1000 mL isotonic crystalloid run over 2-4 hours; actual dosing adjusted per anesthesiologist\u002Fobstetrician and hospital policy). Document exact time, dose, and infusion rate in each case.\n\nSingle rectal dose of misoprostol 600-1000 µg (select dose based on patient risk profile; e.g., 600 µg for routine prophylaxis, 800-1000 µg for high-risk cases) inserted into the rectum immediately after delivery of the baby and placenta. No dilution required.",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"amira zanaty khalaf, resident","CONTACT","01004231328","amirazanatya@gmail.com",{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Amira Zanaty Khalaf Abbas","Resident, Obstetric and Gynecology Department","100607411","rectal-misoprostol-for-reducing-blood-loss-in-elective-cesarean-section-100607411",false,"NCT07188207","Rectal Misoprostol for Reducing Blood Loss in Elective Cesarean Section","The Efficacy of Adding Preoperative Rectal Misoprostol for Decreasing Intraoperative and Postoperative Blood Loss at Elective Cesarean Section","Inclusion Criteria:\n\n* Women aged 18-45 years.\n* Singleton pregnancy at ≥37 weeks of gestation.\n* Elective cesarean section planned under spinal anesthesia.\n* Hemodynamically stable prior to surgery.\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* Multiple pregnancy.\n* Antepartum hemorrhage (e.g., placenta previa, abruption).\n* Coagulopathy, thrombocytopenia, or anticoagulant therapy.\n* Severe medical comorbidities (e.g., uncontrolled hypertension, cardiac disease, hepatic or renal impairment).\n* Known allergy or contraindication to prostaglandins or oxytocin.\n* Intrauterine fetal death or major fetal anomaly.\n* Refusal to participate.","FEMALE","18 Years","45 Years",{"count":46,"type":47},282,"ESTIMATED","INTERVENTIONAL",[50],"NA","This randomized controlled trial aims to evaluate the efficacy of adding preoperative rectal misoprostol to standard oxytocin for reducing intraoperative and postoperative blood loss in women undergoing elective cesarean section. Misoprostol is a prostaglandin E1 analogue that is inexpensive, heat-stable, and effective as a uterotonic agent. The study will compare outcomes between two groups: women receiving oxytocin alone and women receiving oxytocin plus rectal misoprostol. The primary outcome is the reduction of blood loss during and after surgery. Secondary outcomes include changes in hemoglobin levels, need for additional uterotonics, maternal safety, and overall recovery.",[53],"Postpartum Hemorrhage",[55,21,56],"Misoprostol","Cesarean Delivery","NOT_YET_RECRUITING","2025-09-20",{"date":60,"type":61},"2025-09-23","ACTUAL",{"date":63,"type":47},"2025-10-01",{"date":65,"type":47},"2026-12-31",{"name":5,"class":6}]